Jump to contentJump to search

Work-In-Progress Seminar

Work-In-Progress Seminar

For the intensive exchange of information on the current state of the projects, all doctoral students will present and discuss the research results during the work-in-progress seminar in the presence of their supervisor team.

The work-in-progress seminar is combined with the scientific colloquium.

Winter Semester 2021/2022

The colloquia will start at 4:30 pm.

Date Speakers Title
04.10.21 Dr. Christopher Stroh, Director Translational and Biomarker Research, Merck Group A precision medicine approach to target the receptor tyrosine kinase MET in cancer
11.10.21 Guest talk  
18.10.21 Information event on the Feodor Lynen Fellowship of the Alexander von Humboldt Foundation  
25.10.21 Guest talk  
08.11.21 Guest talk  
15.11.21 Progress Reports  
  Julia Gottstein Lantibiotic resistance in human pathogens
  Mariam Dubiel Novel modulators in sphingolipid signaling
22.11.21 Guest talk  
29.11.21 Progress Reports  
  Moritz Klischan Biaryl-based natural products as structural motif for pharmaceutically relevant compounds
  Xiaoli Yang Identification immune activating characteristics of HDAC inhibitors and natural products as novel treatment options for chemoresistant tumors and bacterial pathogens
06.12.21 Dr. Jan Bülle, Kutzenberger Wolff & Partner, Partner, Dipl. Chem., Patentanwalt, European Patent & Trademark Attorney
13.12.21 Progress Reports  
  Emmanuel Adeniyi Characterization of the molecular mechanisms underlying antibacterial activity of natural products
  Lena Berning Characterization of autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells
10.01.22 Guest talk  
17.01.22 Progress Reports  
  Marlena Sekeres Modulation of the DNA damage response (DDR) by natural compounds (NC) to widen the therapeutic window of anticancer drugs
  Pablo Cea Structure based drug design against Nisin resistance systems
24.01.22 Guest talk  
31.01.22 Progress Reports  
  Fabian Fischer Development of chemosensitizing HDAC-Inhibitors, HDAC-PROTACs and HDAC-Inhibitors with fluorescent Cap-groups
  Flaminia Mazzone Identification and characterization of new natural products with anti-microbial activity against Apicomplexa and multiresistant gram-negative rods (4MRGN)

Summer Semester 2021

The colloquia will take place as online meetings starting at 4:30 pm. The invitation link will be send by email.

Date Speakers Title
19.04.21 Progress Reports  
  Flaminia Mazzone Identification and characterization of new natural products with anti-microbial activity against Apicomplexa and multiresistant gram-negative rods (4MRGN)
  Laura Mayer Diversity-oriented synthesis of diaryl substituted heterocycles via sequential palladium catalysis
26.04.21 Progress Reports  
  Pablo Cea Structural studies of nisin resistance and immunity systems
  Lars Seiffert Synthesis of small-molecule inhibitors of nisin resistance protein
10.05.21 Progress Reports  
  Julian Schliehe-Diecks Characterization of synergy and resistance traits of HSP90 and HDAC inhibitors in leukemic cell lines
  Fabian Fischer Development of chemosensitizing HDAC-Inhibitors and HDAC-PROTACs
17.05.21 Dr. Christine Beemelmanns, Junior Research Group Leader Chemical Biology of Microbe-Host Interactions, Leibniz Institute for Natural Product Research and Infection Biology e.V., Hans-Knöll-Institute (HKI) Novel Secondary Metabolites from Microbial Interactions
31.05.21 Prof. Dr. Dominic Hoepfner, Director Genomic Sciences, Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research How to catch a target: genetic fishing expeditions with natural products
07.06.21 Progress Reports  
  Korana Mudrovcic Exploration of Strategies to Disrupt ULK1 Protein Complex and Chlorflavonin Optimization
  Annabelle Friedrich Targeting protein-protein interactions within the autophagy-inducing ULK1 complex for cancer therapy
14.06.21 Dr. Bert Klebl, Managing Director and Chief Scientific Officer of Lead Discovery Center GmbH, Dortmund, Germany Pandemic Prepardness – a Pathoblocker Concept to Inhibit S. aureus Induced Infections
21.06.21 Progress Reports  
  Talea Knak Structural optimization of Chlorflavonin – a natural product with antimycobacterial activity
  Ilka Hinxlage Identification of Novel Apoptotic Signaling Pathways for the Elimination of Therapy-Resistant Tumors
28.06.21 Dr. Elke Röhrdanz, Head of the Unit Reproductive and Genetic Toxicology, BfArM (Federal Institute for Drugs and Medical Devices) Non-clinical Drug Development
05.07.21 cancelled  
12.07.21 Prof. Dr. Zoe Waibler, Paul-​Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Batch testing and batch release of immunological biomedicines in Germany
Responsible for the content: